Exact Mass: 674.5121
Exact Mass Matches: 674.5121
Found 500 metabolites which its exact mass value is equals to given mass value 674.5121,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
PA(16:0/18:1(9Z))
PA(16:0/18:1(9Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(16:0/18:1(9Z)), in particular, consists of one chain of palmitic acid at the C-1 position and one chain of oleic acid at the C-2 position. The palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats, while the oleic acid moiety is derived from vegetable oils, especially olive and canola oil. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids. Indeed, the concentration of phosphatidic acids is often over-estimated in tissues and biofluids as it can arise by inadvertent enzymatic hydrolysis during inappropriate storage or extraction conditions during analysis. The main biosynthetic route of phosphatidic acid in animal tissues involves sequential acylation of alpha-glycerophosphate by acyl-coA derivatives of fatty acids. PAs are biologically active lipids that can stimulate a large range of responses in many different cell types, such as platelet aggregation, smooth muscle contraction, in vivo vasoactive effects, chemotaxis, expression of adhesion molecules, increased tight junction permeability of endothelial cells, induction of stress fibres, modulation of cardiac contractility, and many others. Diacylglycerols (DAGs) can be converted to PAs by DAG kinases and indirect evidence supports the notion that PAs alter the excitability of neurons. Phospholipase Ds (PLDs), which catalyze the conversion of glycerolphospholipids, particularly phosphatidylcholine, to PAs and the conversion of N-arachidonoyl-phosphatidylethanolamine (NAPE) to anandamide and PAs are activated by several inflammatory mediators including bradykinin, ATP and glutamate. PAs activate downstream signaling pathways such as PKCs and mitogen-activated protein kinases (MAPKs), which are linked to an increase in sensitivity of sensory neurons either during inflammation or in chronic pain models. Circumstantial evidence that PAs are converted to DAGs. (PMID: 12618218, 16185776). [HMDB] PA(16:0/18:1(9Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(16:0/18:1(9Z)), in particular, consists of one chain of palmitic acid at the C-1 position and one chain of oleic acid at the C-2 position. The palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats, while the oleic acid moiety is derived from vegetable oils, especially olive and canola oil. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids. Indeed, the concentration of phosphatidic acids is often over-estimated in tissues and biofluids as it can arise by inadvertent enzymatic hydrolysis during inappropriate storage or extraction conditions during analysis. The main biosynthetic route of phosphatidic acid in animal tissues involves sequential acylation of alpha-glycerophosphate by acyl-CoA derivatives of fatty acids. PAs are biologically active lipids that can stimulate a large range of responses in many different cell types, such as platelet aggregation, smooth muscle contraction, in vivo vasoactive effects, chemotaxis, expression of adhesion molecules, increased tight junction permeability of endothelial cells, induction of stress fibres, modulation of cardiac contractility, and many others. Diacylglycerols (DAGs) can be converted to PAs by DAG kinases and indirect evidence supports the notion that PAs alter the excitability of neurons. Phospholipase Ds (PLDs), which catalyze the conversion of glycerolphospholipids, particularly phosphatidylcholine, to PAs and the conversion of N-arachidonoyl-phosphatidylethanolamine (NAPE) to anandamide and PAs are activated by several inflammatory mediators including bradykinin, ATP and glutamate. PAs activate downstream signaling pathways such as PKCs and mitogen-activated protein kinases (MAPKs), which are linked to an increase in sensitivity of sensory neurons either during inflammation or in chronic pain models. Circumstantial evidence that PAs are converted to DAGs. (PMID: 12618218, 16185776).
9-Octadecenoic acid 1-[[(1-oxohexadecyl)oxy]methyl]-2-(phosphonoxy)ethyl ester
9-Octadecenoic acid 1-[[(1-oxohexadecyl)oxy]methyl]-2-(phosphonoxy)ethyl ester is classified as a Natural Food Constituent (code WA) in the DF Classified as a Natural Food Constituent (code WA) in the DFC
PA(16:0/18:1(11Z))
PA(16:0/18:1(11Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(16:0/18:1(11Z)), in particular, consists of one chain of palmitic acid at the C-1 position and one chain of vaccenic acid at the C-2 position. The palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats, while the vaccenic acid moiety is derived from butter fat and animal fat. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids. Indeed, the concentration of phosphatidic acids is often over-estimated in tissues and biofluids as it can arise by inadvertent enzymatic hydrolysis during inappropriate storage or extraction conditions during analysis. The main biosynthetic route of phosphatidic acid in animal tissues involves sequential acylation of alpha-glycerophosphate by acyl-coA derivatives of fatty acids. PAs are biologically active lipids that can stimulate a large range of responses in many different cell types, such as platelet aggregation, smooth muscle contraction, in vivo vasoactive effects, chemotaxis, expression of adhesion molecules, increased tight junction permeability of endothelial cells, induction of stress fibres, modulation of cardiac contractility, and many others. Diacylglycerols (DAGs) can be converted to PAs by DAG kinases and indirect evidence supports the notion that PAs alter the excitability of neurons. Phospholipase Ds (PLDs), which catalyze the conversion of glycerolphospholipids, particularly phosphatidylcholine, to PAs and the conversion of N-arachidonoyl-phosphatidylethanolamine (NAPE) to anandamide and PAs are activated by several inflammatory mediators including bradykinin, ATP and glutamate. PAs activate downstream signaling pathways such as PKCs and mitogen-activated protein kinases (MAPKs), which are linked to an increase in sensitivity of sensory neurons either during inflammation or in chronic pain models. Circumstantial evidence that PAs are converted to DAGs. (PMID: 12618218, 16185776). [HMDB] PA(16:0/18:1(11Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(16:0/18:1(11Z)), in particular, consists of one chain of palmitic acid at the C-1 position and one chain of vaccenic acid at the C-2 position. The palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats, while the vaccenic acid moiety is derived from butter fat and animal fat. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids. Indeed, the concentration of phosphatidic acids is often over-estimated in tissues and biofluids as it can arise by inadvertent enzymatic hydrolysis during inappropriate storage or extraction conditions during analysis. The main biosynthetic route of phosphatidic acid in animal tissues involves sequential acylation of alpha-glycerophosphate by acyl-CoA derivatives of fatty acids. PAs are biologically active lipids that can stimulate a large range of responses in many different cell types, such as platelet aggregation, smooth muscle contraction, in vivo vasoactive effects, chemotaxis, expression of adhesion molecules, increased tight junction permeability of endothelial cells, induction of stress fibres, modulation of cardiac contractility, and many others. Diacylglycerols (DAGs) can be converted to PAs by DAG kinases and indirect evidence supports the notion that PAs alter the excitability of neurons. Phospholipase Ds (PLDs), which catalyze the conversion of glycerolphospholipids, particularly phosphatidylcholine, to PAs and the conversion of N-arachidonoyl-phosphatidylethanolamine (NAPE) to anandamide and PAs are activated by several inflammatory mediators including bradykinin, ATP and glutamate. PAs activate downstream signaling pathways such as PKCs and mitogen-activated protein kinases (MAPKs), which are linked to an increase in sensitivity of sensory neurons either during inflammation or in chronic pain models. Circumstantial evidence that PAs are converted to DAGs. (PMID: 12618218, 16185776).
SM(d18:1/14:0)
Sphingomyelin (d18:1/14:0) or SM(d18:1/14:0) is a type of sphingolipid found in animal cell membranes, especially in the membranous myelin sheath which surrounds some nerve cell axons. It usually consists of phosphorylcholine and ceramide. SM(d18:1/14:0) consists of a sphingosine backbone and a myristic acid chain. In humans, sphingomyelin is the only membrane phospholipid not derived from glycerol. Like all sphingolipids, SM has a ceramide core (sphingosine bonded to a fatty acid via an amide linkage). In addition, it contains one polar head group, which is either phosphocholine or phosphoethanolamine. The plasma membrane of cells is highly enriched in sphingomyelin and is considered largely to be found in the exoplasmic leaflet of the cell membrane. However, there is some evidence that there may also be a sphingomyelin pool in the inner leaflet of the membrane. Moreover, neutral sphingomyelinase-2, an enzyme that breaks down sphingomyelin into ceramide, has been found to localize exclusively to the inner leaflet further suggesting that there may be sphingomyelin present there. Sphingomyelin can accumulate in a rare hereditary disease called Niemann-Pick Disease, types A and B. Niemann-Pick disease is a genetically-inherited disease caused by a deficiency in the enzyme sphingomyelinase, which causes the accumulation of sphingomyelin in spleen, liver, lungs, bone marrow, and the brain, causing irreversible neurological damage. SMs play a role in signal transduction. Sphingomyelins are synthesized by the transfer of phosphorylcholine from phosphatidylcholine to a ceramide in a reaction catalyzed by sphingomyelin synthase. Not Available
PA(18:0/16:1(9Z))
PA(18:0/16:1(9Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:0/16:1(9Z)), in particular, consists of one chain of stearic acid at the C-1 position and one chain of palmitoleic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(18:1(11Z)/16:0)
PA(18:1(11Z)/16:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:1(11Z)/16:0), in particular, consists of one chain of cis-vaccenic acid at the C-1 position and one chain of palmitic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(18:1(9Z)/16:0)
PA(18:1(9Z)/16:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:1(9Z)/16:0), in particular, consists of one chain of oleic acid at the C-1 position and one chain of palmitic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(20:0/14:1(9Z))
PA(20:0/14:1(9Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:0/14:1(9Z)), in particular, consists of one chain of arachidic acid at the C-1 position and one chain of myristoleic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(20:1(11Z)/14:0)
PA(20:1(11Z)/14:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:1(11Z)/14:0), in particular, consists of one chain of eicosenoic acid at the C-1 position and one chain of myristic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
SM(d16:1/16:0)
Sphingomyelin (d16:1/16:0) or SM(d16:1/16:0) is a type of sphingolipid found in animal cell membranes, especially in the membranous myelin sheath which surrounds some nerve cell axons. It usually consists of phosphorylcholine and ceramide. SM(d16:1/16:0) consists of a hexadecasphingosine backbone and a palmitic acid chain. In humans, sphingomyelin is the only membrane phospholipid not derived from glycerol. Like all sphingolipids, SM has a ceramide core (sphingosine bonded to a fatty acid via an amide linkage). In addition, it contains one polar head group, which is either phosphocholine or phosphoethanolamine. The plasma membrane of cells is highly enriched in sphingomyelin and is considered largely to be found in the exoplasmic leaflet of the cell membrane. However, there is some evidence that there may also be a sphingomyelin pool in the inner leaflet of the membrane. Moreover, neutral sphingomyelinase-2, an enzyme that breaks down sphingomyelin into ceramide, has been found to localize exclusively to the inner leaflet further suggesting that there may be sphingomyelin present there. Sphingomyelin can accumulate in a rare hereditary disease called Niemann-Pick Disease, types A and B. Niemann-Pick disease is a genetically-inherited disease caused by a deficiency in the enzyme sphingomyelinase, which causes the accumulation of sphingomyelin in spleen, liver, lungs, bone marrow, and the brain, causing irreversible neurological damage. SMs play a role in signal transduction. Sphingomyelins are synthesized by the transfer of phosphorylcholine from phosphatidylcholine to a ceramide in a reaction catalyzed by sphingomyelin synthase.
DG(18:0/PGJ2/0:0)
DG(18:0/PGJ2/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(18:0/PGJ2/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(PGJ2/18:0/0:0)
DG(PGJ2/18:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(PGJ2/18:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(18:0/0:0/PGJ2)
DG(18:0/0:0/PGJ2) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(PGJ2/0:0/18:0)
DG(PGJ2/0:0/18:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(i-18:0/PGJ2/0:0)
DG(i-18:0/PGJ2/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(i-18:0/PGJ2/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(PGJ2/i-18:0/0:0)
DG(PGJ2/i-18:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(PGJ2/i-18:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(i-18:0/0:0/PGJ2)
DG(i-18:0/0:0/PGJ2) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(PGJ2/0:0/i-18:0)
DG(PGJ2/0:0/i-18:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
1-(O-alpha-D-glucopyranosyl)-29-keto-(3R,31R)-dotriacontanediol
[1-hexadecanoyloxy-3-phosphonooxypropan-2-yl]octadec-9-enoate
(2-{[3-hydroxy-2-tetradecanamidooctadec-4-en-1-yl phosphonato]oxy}ethyl)trimethylazanium
PE-Cer(d14:1(4E)/20:1(11Z)(2OH))
PE-Cer(d14:2(4E,6E)/20:0(2OH))
PE-Cer(d16:1(4E)/18:1(9Z)(2OH))
PE-Cer(d16:2(4E,6E)/18:0(2OH))
PA(16:0/18:1)
1-(O-alpha-D-glucopyranosyl)-29-keto-(1,3R,31R)-dotriacontanetriol
1-(O-alpha-D-mannopyranosyl)-29-keto-(1,3R,31R)-dotriacontanetriol
[2-(hexadecanoyloxy)-3-[(9E)-octadec-9-enoyloxy]propoxy]phosphonic acid
(2R)-3-(palmitoyloxy)-2-(stearoyloxy)propyl phosphate
1-O-(alpha-D-glucosyl)-29-keto-(3R,31R)-dotriacontanetriol
An alpha-D-glucoside that is 29-keto-(3R,31R)-dotriacontanetriol having a single alpha-D-glucosyl residue attached at position 1.
1-Hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycerol 3-phosphate
[(2R)-1-hexadecanoyloxy-3-phosphonooxypropan-2-yl] (E)-octadec-9-enoate
[2-Tetradecanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] tetradecanoate
[(E)-2-acetamido-3-hydroxytriacont-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-hydroxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]propan-2-yl] (9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoate
[1-hydroxy-3-[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoxy]propan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate
[1-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoxy]-3-hydroxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
[(E)-3-hydroxy-2-(propanoylamino)nonacos-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[(E)-3-hydroxy-2-(tricosanoylamino)non-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[(8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-8,11,14,17,20,23-hexaenoxy]-3-hydroxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
[1-[(5Z,8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-5,8,11,14,17,20,23-heptaenoxy]-3-hydroxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
[1-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]-3-hydroxypropan-2-yl] (8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-8,11,14,17,20,23-hexaenoate
[(E)-3-hydroxy-2-(tetracosanoylamino)oct-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-hydroxy-3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]propan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate
[(E)-2-(butanoylamino)-3-hydroxyoctacos-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[(E)-2-(hexanoylamino)-3-hydroxyhexacos-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[(E)-3-hydroxy-2-(pentanoylamino)heptacos-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-hydroxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate
[(E)-3-hydroxy-2-(nonanoylamino)tricos-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[(E)-2-(heptanoylamino)-3-hydroxypentacos-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[(E)-3-hydroxy-2-(octanoylamino)tetracos-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]-3-hydroxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-5,8,11,14,17,20,23-heptaenoate
[1-hydroxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propan-2-yl] (6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoate
[1-hydroxy-3-[(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoxy]propan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
[1-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoxy]-3-hydroxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate
[2-[[(Z)-hexadec-9-enoyl]amino]-3-hydroxyhexadecyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]nonadecyl] 2-(trimethylazaniumyl)ethyl phosphate
[(E)-2-(docosanoylamino)-3-hydroxydec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[[(Z)-docos-13-enoyl]amino]-3-hydroxydecyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-hydroxy-2-[[(Z)-octadec-9-enoyl]amino]tetradecyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-hydroxy-2-[[(Z)-icos-11-enoyl]amino]dodecyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[[(Z)-heptadec-9-enoyl]amino]-3-hydroxypentadecyl] 2-(trimethylazaniumyl)ethyl phosphate
[(E)-3-hydroxy-2-(nonadecanoylamino)tridec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[(E)-3-hydroxy-2-(undecanoylamino)henicos-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[(E)-2-(decanoylamino)-3-hydroxydocos-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[[(Z)-henicos-11-enoyl]amino]-3-hydroxyundecyl] 2-(trimethylazaniumyl)ethyl phosphate
[(E)-3-hydroxy-2-(icosanoylamino)dodec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-hydroxy-2-[[(Z)-nonadec-9-enoyl]amino]tridecyl] 2-(trimethylazaniumyl)ethyl phosphate
[(E)-2-(henicosanoylamino)-3-hydroxyundec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-Heptanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] henicosanoate
[1-Propanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] pentacosanoate
[1-Hexanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] docosanoate
[1-Octanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] icosanoate
[1-Pentanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] tricosanoate
[1-Acetyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] hexacosanoate
[1-Butanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] tetracosanoate
[1-Nonanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] nonadecanoate
[1-Dodecanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] hexadecanoate
[1-Decanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] octadecanoate
[1-[3,4,5-Trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-undecanoyloxypropan-2-yl] heptadecanoate
[1-Tridecanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] pentadecanoate
[3-hydroxy-2-[[(Z)-tetracos-13-enoyl]amino]octyl] 2-(trimethylazaniumyl)ethyl phosphate
[(E)-3-hydroxy-2-(tetradecanoylamino)octadec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[(E)-3-hydroxy-2-(pentadecanoylamino)heptadec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[(E)-2-(heptadecanoylamino)-3-hydroxypentadec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-hydroxy-2-[[(Z)-pentadec-9-enoyl]amino]heptadecyl] 2-(trimethylazaniumyl)ethyl phosphate
[(E)-3-hydroxy-2-(tridecanoylamino)nonadec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[(E)-2-(dodecanoylamino)-3-hydroxyicos-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[(E)-3-hydroxy-2-(octadecanoylamino)tetradec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[(E)-2-(hexadecanoylamino)-3-hydroxyhexadec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]octadecyl] 2-(trimethylazaniumyl)ethyl phosphate
(1-octanoyloxy-3-phosphonooxypropan-2-yl) (Z)-hexacos-15-enoate
(1-dodecanoyloxy-3-phosphonooxypropan-2-yl) (Z)-docos-13-enoate
(1-phosphonooxy-3-tridecanoyloxypropan-2-yl) (Z)-henicos-11-enoate
(1-phosphonooxy-3-tetradecanoyloxypropan-2-yl) (Z)-icos-11-enoate
[2-[(Z)-hexadec-9-enoyl]oxy-3-phosphonooxypropyl] octadecanoate
(1-decanoyloxy-3-phosphonooxypropan-2-yl) (Z)-tetracos-13-enoate
(1-pentadecanoyloxy-3-phosphonooxypropan-2-yl) (Z)-nonadec-9-enoate
[3-phosphonooxy-2-[(Z)-tridec-9-enoyl]oxypropyl] henicosanoate
[2-[(Z)-pentadec-9-enoyl]oxy-3-phosphonooxypropyl] nonadecanoate
[2-[(Z)-heptadec-9-enoyl]oxy-3-phosphonooxypropyl] heptadecanoate
[3-phosphonooxy-2-[(Z)-tetradec-9-enoyl]oxypropyl] icosanoate
[(2R)-1-hexadecanoyloxy-3-phosphonooxypropan-2-yl] (E)-octadec-11-enoate
[3-hydroxy-2-[[(Z)-tridec-8-enoyl]amino]nonadecyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-hydroxy-2-[[(Z)-octadec-11-enoyl]amino]tetradecyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[[(Z)-hexadec-7-enoyl]amino]-3-hydroxyhexadecyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[[(Z)-dodec-5-enoyl]amino]-3-hydroxyicosyl] 2-(trimethylazaniumyl)ethyl phosphate
[(E)-3,4-dihydroxy-2-[[(Z)-tridec-9-enoyl]amino]octadec-8-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[(8E,12E)-3,4-dihydroxy-2-(tridecanoylamino)octadeca-8,12-dienyl] 2-(trimethylazaniumyl)ethyl phosphate
N-(pentadecanoyl)-4E-heptadecasphingenine-1-phosphocholine
N-(heptadecanoyl)-4E-pentadecasphingenine-1-phosphocholine
N-(tridecanoyl)-4E-nonadecasphingenine-1-phosphocholine
N-(dodecanoyl)-4E-eicosasphingenine-1-phosphocholine
N-(octadecanoyl)-4E-tetradecasphingenine-1-phosphocholine
[(2R)-1-[(E)-heptadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] heptadecanoate
[1-carboxy-3-[2-decanoyloxy-3-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[3-[(7E,10E,13E,16E)-nonadeca-7,10,13,16-tetraenoyl]oxy-2-[(E)-undec-4-enoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[3-[(E)-dodec-5-enoyl]oxy-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-tetradecanoyloxypropoxy]propyl]-trimethylazanium
[(E,2R,3S)-2-(decanoylamino)-3-hydroxydocos-8-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-carboxy-3-[2-[(6E,9E)-dodeca-6,9-dienoyl]oxy-3-[(11E,13E,15E)-octadeca-11,13,15-trienoyl]oxypropoxy]propyl]-trimethylazanium
[(2R)-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-undecanoyloxypropyl] heptadecanoate
[(2R)-1-dodecanoyloxy-3-phosphonooxypropan-2-yl] (E)-docos-13-enoate
[(2R)-2-dodecanoyloxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] hexadecanoate
[1-carboxy-3-[2-[(4E,7E)-deca-4,7-dienoyl]oxy-3-[(5E,8E,11E)-icosa-5,8,11-trienoyl]oxypropoxy]propyl]-trimethylazanium
[1-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-hydroxypropan-2-yl] (10E,13E,16E,19E,22E)-pentacosa-10,13,16,19,22-pentaenoate
[(2R)-1-[(E)-hexadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] octadecanoate
[(2R)-1-phosphonooxy-3-tetradecanoyloxypropan-2-yl] (E)-icos-13-enoate
[(2R)-2-hexadecanoyloxy-3-phosphonooxypropyl] (E)-octadec-13-enoate
[1-carboxy-3-[2-dodecanoyloxy-3-[(7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[3-[(9E,12E)-pentadeca-9,12-dienoyl]oxy-2-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[2-[(E)-dec-4-enoyl]oxy-3-[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]oxypropoxy]propyl]-trimethylazanium
[(2S)-1-decanoyloxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] octadecanoate
[(2R)-1-[(E)-hexadec-7-enoyl]oxy-3-phosphonooxypropan-2-yl] octadecanoate
[(2S,3R)-2-[[(E)-hexadec-9-enoyl]amino]-3-hydroxyhexadecyl] 2-(trimethylazaniumyl)ethyl phosphate
[(2R)-2-[(E)-hexadec-7-enoyl]oxy-3-phosphonooxypropyl] octadecanoate
[(2R)-3-phosphonooxy-2-tetradecanoyloxypropyl] (E)-icos-13-enoate
[(2S)-2-tetradecanoyloxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] tetradecanoate
[1-carboxy-3-[3-dodecanoyloxy-2-[(7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[3-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-2-[(E)-tetradec-9-enoyl]oxypropoxy]propyl]-trimethylazanium
[(2R)-2-decanoyloxy-3-phosphonooxypropyl] (E)-tetracos-15-enoate
[(2R)-2-hexadecanoyloxy-3-phosphonooxypropyl] (E)-octadec-7-enoate
[(2R)-1-hexadecanoyloxy-3-phosphonooxypropan-2-yl] (E)-octadec-13-enoate
[1-carboxy-3-[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropoxy]propyl]-trimethylazanium
[(2R)-1-phosphonooxy-3-tetradecanoyloxypropan-2-yl] (E)-icos-11-enoate
[(E,2S,3R)-2-(hexadecanoylamino)-3-hydroxyhexadec-8-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[(2R)-1-phosphonooxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] icosanoate
[(2S)-1-dodecanoyloxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] hexadecanoate
[1-carboxy-3-[3-[(4E,7E)-deca-4,7-dienoyl]oxy-2-[(5E,8E,11E)-icosa-5,8,11-trienoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[2-[(E)-dodec-5-enoyl]oxy-3-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[3-[(4E,7E,10E,13E,16E)-nonadeca-4,7,10,13,16-pentaenoyl]oxy-2-undecanoyloxypropoxy]propyl]-trimethylazanium
[(2R)-2-hexadecanoyloxy-3-phosphonooxypropyl] (E)-octadec-11-enoate
[(E,2S,3R)-3-hydroxy-2-(tetradecanoylamino)octadec-8-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[(2R)-2-hexadecanoyloxy-3-phosphonooxypropyl] (E)-octadec-6-enoate
[(2R)-2-[(E)-hexadec-9-enoyl]oxy-3-phosphonooxypropyl] octadecanoate
[(2R)-1-hexadecanoyloxy-3-phosphonooxypropan-2-yl] (E)-octadec-6-enoate
[1-carboxy-3-[3-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-2-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropoxy]propyl]-trimethylazanium
[(2R)-2-hexadecanoyloxy-3-phosphonooxypropyl] (E)-octadec-4-enoate
[(E,2S,3R)-2-(heptadecanoylamino)-3-hydroxypentadec-8-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[(E,2S,3R)-2-(dodecanoylamino)-3-hydroxyicos-8-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[(2R)-1-hexadecanoyloxy-3-phosphonooxypropan-2-yl] (E)-octadec-4-enoate
[(2R)-2-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropyl] nonadecanoate
[(2R)-1-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] nonadecanoate
[(2R)-1-hexadecanoyloxy-3-phosphonooxypropan-2-yl] (E)-octadec-7-enoate
[(2R)-1-hexadecanoyloxy-3-phosphonooxypropan-2-yl] octadec-17-enoate
[(2S,3R)-3-hydroxy-2-[[(E)-octadec-9-enoyl]amino]tetradecyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-carboxy-3-[3-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-2-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[3-[(6E,9E)-dodeca-6,9-dienoyl]oxy-2-[(11E,13E,15E)-octadeca-11,13,15-trienoyl]oxypropoxy]propyl]-trimethylazanium
[1-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-hydroxypropan-2-yl] (7E,10E,13E,16E,19E,22E)-pentacosa-7,10,13,16,19,22-hexaenoate
[1-carboxy-3-[2-[(9E,12E)-pentadeca-9,12-dienoyl]oxy-3-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropoxy]propyl]-trimethylazanium
[(2R)-2-[(E)-heptadec-9-enoyl]oxy-3-phosphonooxypropyl] heptadecanoate
[(2R)-2-dodecanoyloxy-3-phosphonooxypropyl] (E)-docos-13-enoate
[(2S)-1-tridecanoyloxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] pentadecanoate
[1-carboxy-3-[2-[(7E,10E,13E,16E)-nonadeca-7,10,13,16-tetraenoyl]oxy-3-[(E)-undec-4-enoyl]oxypropoxy]propyl]-trimethylazanium
[(2S,3R)-2-[[(E)-heptadec-9-enoyl]amino]-3-hydroxypentadecyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-carboxy-3-[3-decanoyloxy-2-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxypropoxy]propyl]-trimethylazanium
[(2R)-2-tridecanoyloxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] pentadecanoate
[1-carboxy-3-[2-[(4E,7E,10E,13E,16E)-nonadeca-4,7,10,13,16-pentaenoyl]oxy-3-undecanoyloxypropoxy]propyl]-trimethylazanium
[(2R)-2-decanoyloxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] octadecanoate
[1-carboxy-3-[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropoxy]propyl]-trimethylazanium
[(2R)-1-decanoyloxy-3-phosphonooxypropan-2-yl] (E)-tetracos-15-enoate
[1-carboxy-3-[3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-2-[(10E,12E)-octadeca-10,12-dienoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[3-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-2-tetradecanoyloxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[3-[(E)-dec-4-enoyl]oxy-2-[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[2-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-3-[(10E,12E)-octadeca-10,12-dienoyl]oxypropoxy]propyl]-trimethylazanium
[(E,2R,3S)-2-(decanoylamino)-3-hydroxydocos-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[(E,2S,3R)-3-hydroxy-2-(tridecanoylamino)nonadec-8-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[(2R)-3-phosphonooxy-2-tetradecanoyloxypropyl] (E)-icos-11-enoate
[1-carboxy-3-[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[(E)-tetradec-9-enoyl]oxypropoxy]propyl]-trimethylazanium
[(E,2S,3R)-3-hydroxy-2-(pentadecanoylamino)heptadec-8-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[(2R)-3-phosphonooxy-2-[(E)-tetradec-9-enoyl]oxypropyl] icosanoate
[(E,2S,3R)-3-hydroxy-2-(octadecanoylamino)tetradec-8-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[(2R)-2-hexadecanoyloxy-3-phosphonooxypropyl] octadec-17-enoate
[(2S)-1-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-undecanoyloxypropan-2-yl] heptadecanoate
[(2R)-2-hexadecanoyloxy-3-phosphonooxypropyl] (E)-octadec-9-enoate
[1-carboxy-3-[2-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyl]oxy-3-octanoyloxypropoxy]propyl]-trimethylazanium
2-[[3-[(9Z,12Z)-hexadeca-9,12-dienoxy]-2-tridecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
[1-carboxy-3-[3-dodecanoyloxy-2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxypropoxy]propyl]-trimethylazanium
2-[[3-[(Z)-hexadec-9-enoxy]-2-[(Z)-tridec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
[1-carboxy-3-[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[3-decanoyloxy-2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxypropoxy]propyl]-trimethylazanium
2-[hydroxy-[2-[(Z)-pentadec-9-enoyl]oxy-3-[(Z)-tetradec-9-enoxy]propoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-[(9Z,12Z)-octadeca-9,12-dienoxy]-2-undecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium
2-[carboxy-[2-hydroxy-3-[(12Z,15Z,18Z,21Z,24Z,27Z)-triaconta-12,15,18,21,24,27-hexaenoyl]oxypropoxy]methoxy]ethyl-trimethylazanium
2-[[2-[(11Z,14Z)-henicosa-11,14-dienoyl]oxy-3-octoxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxy-3-undecoxypropoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-[(11Z,14Z)-icosa-11,14-dienoxy]-2-nonanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[2-decanoyloxy-3-[(9Z,12Z)-nonadeca-9,12-dienoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-[(Z)-pentadec-9-enoxy]-2-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[3-[(13Z,16Z)-docosa-13,16-dienoxy]-2-heptanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[3-decoxy-2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[2-[(11Z,14Z)-icosa-11,14-dienoyl]oxy-3-nonoxypropoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[2-dodecanoyloxy-3-[(9Z,12Z)-heptadeca-9,12-dienoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-tridecoxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[3-[(11Z,14Z)-henicosa-11,14-dienoxy]-2-octanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[3-dodecoxy-2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-[(Z)-hexadec-9-enoyl]oxy-3-[(Z)-tridec-9-enoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[2-pentanoyloxy-3-[(13Z,16Z)-tetracosa-13,16-dienoxy]propoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[3-[(15Z,18Z)-hexacosa-15,18-dienoxy]-2-propanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
1-oleoyl-2-palmitoyl-sn-glycero-3-phosphate
A 1-acyl-2-hexadecanoyl-sn-glycero-3-phosphate in which the 1-acyl group is specified as oleoyl (9Z-octadecaenoyl).
N-myristoylsphingosine-1-phosphocholine
A sphingomyelin d18:1 in which the N-acyl group is specified as tetradecanoyl (myristoyl).
1-octadecanoyl-2-(9Z)-hexadecenoyl-sn-glycero-3-phosphate
A 1,2-diacyl-sn-glycerol 3-phosphate in which the acyl substituents at positions 1 and 2 are specified as octadecanoyl and (9Z)-hexadecenoyl respectively.
1-eicosanoyl-2-(9Z-tetradecenoyl)-glycero-3-phosphate
1-(11Z-eicosenoyl)-2-tetradecanoyl-glycero-3-phosphate
N-(hexadecanoyl)-hexadecasphing-4-enine-1-phosphocholine
9-Octadecenoic acid 1-[[(1-oxohexadecyl)oxy]methyl]-2-(phosphonoxy)ethyl ester
1-tetradecanoyl-2-(11Z-eicosenoyl)-glycero-3-phosphate
1-dodecanoyl-2-(11Z-docosenoyl)-glycero-3-phosphate
1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphate(2-)
A 1-acyl-2-octadecanoyl-sn-glycero-3-phosphate(2-) in which the 1-acyl group is specified as hexadecanoyl (palmitoyl); major species at pH 7.3.
N-(heneicosanoyl)-tetradecasphing-4-enine-1-phosphoethanolamine
A N-acyltetradecasphingosine-1-phosphoethanolamine in which the acyl group specified is heneicosanoyl.
1-octadecyl-2-(9Z-heptadecenoyl)-glycero-3-phosphate
1-(9Z-pentadecenoyl)-2-nonadecanoyl-glycero-3-phosphate
1-(9Z-heptadecenoyl)-2-heptadecanoyl-glycero-3-phosphate
1-nonadecanoyl-2-(9Z-pentadecenoyl)-glycero-3-phosphate
1-(9Z-tetradecenoyl)-2-eicosanoyl-glycero-3-phosphate
1-pentadecanoyl-2-(9Z-nonadecenoyl)-glycero-3-phosphate
1-(9Z-hexadecenoyl)-2-octadecanoyl-glycero-3-phosphate
1-heptadecanoyl-2-(9Z-heptadecenoyl)-glycero-3-phosphate
1-(9Z-nonadecenoyl)-2-pentadecanoyl-glycero-3-phosphate
1-(11Z-docosenoyl)-2-dodecanoyl-glycero-3-phosphate
(1-Hexadecanoyloxy-3-phosphonooxypropan-2-yl) octadec-9-enoate
phosphatidic acid (16:0/18:1)
A phosphatidic acid in which one acyl group has 16 carbons and is fully saturated while the other has 18 carbons and 1 double bond.
sphingomyelin 32:1
A sphingomyelin in which the total number of carbons in the sphingoid base (R1) and fatty acyl (R2) groups is 32 with 1 double bond.
ceramide phosphoethanolamine (35:1)
A ceramide phosphoethanolamine in which the sphingoid base and acyl group contains a total of 35 carbon atoms and 1 double bond.
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphate
A 1,2-diacyl-sn-glycerol 3-phosphate in which the 1- and 2-acyl groups are palmitoyl and oleoyl respectively.
N-(hexadecanoyl)hexadecasphingosine-1-phosphocholine
An N-acylhexadecasphingosine-1-phosphocholine in which the ceramide N-acyl group is specified as hexadecanoyl (palmitoyl).
BisMePA(32:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
MGMG(29:0)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
MGDG(28:0)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
